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Dr Bavaria. We will start some discussion from the floor.
Dr S. Vitale (Valhalla, NY). I was just wondering whether you
can elaborate on the use of naloxone for spinal cord protection
because I have not seen any good data that support it.
Dr Acher. Yes, I can. There are no level I data, but the experi-
mental data are quite clear that endorphins have a very negative
effect on injured spinal neurons and that endorphin receptor antag-
onists are effective in protecting the spinal cord experimentally. It
has also been shown lately that naloxone reduces the release of
excitatory amino acids in spinal fluid of patients undergoing
elective aortic resection–thoracoabdominal repair. This is by the
Japanese author Kunihara in the Journal of Vascular Surgery in
2004. But more importantly, the issue for us when we introduced
its use was the experimental literature on use of high-dose nalox-
one, which was unacceptable because of its analgesic reversal.
Therefore the first patient we used it on was a patient with spinal
fluid drainage who woke up with weakness, and I observed her
getting progressively weaker over the next few hours. I called my
anesthesiologist and said, ‘‘What is the lowest dose of naloxone
that has a central nervous system effect?’’; it was the dose that
reverses apnea associated with epidural narcotics. We used that
dose, and 2 hours later, the patient had normal neurologic function.
We repeated that observation in the next patient who woke up weak
with spinal fluid drainage and had the same result over a longer
period of time and have used it ever since. We do think it is an
important part of our protocol. We presented that in 1989. It was
published in 1990 in our first series of 42 patients.d at Aortic Surgery Symposium 2010, New York, NY, Friday, April 30, 2010.
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The Journal of Thoracic and Cardiovascular SurDr Bavaria. Marc, do you ever use any naloxone?
Dr Schepens. I have no experience with the use of naloxone.
Dr Bavaria. Drs Griepp and Estrera, do you use naloxone,
except for rescue maybe?
Dr Estrera. No.
Dr Griepp. No, we have not, either.
Dr R. Calhoun (Sacramento, Calif). This is a more appropri-
ately timed question today than yesterday, but it is the same ques-
tion. For the occasional acute type A dissection in the operating
room, in which it is clear that the tear is beyond the ascending aorta,
either up in the arch or perhaps even more distally, I am curious
about the philosophy of the panel in terms of your aggressiveness
about going after that tear as opposed to just replacing the ascend-
ing aorta and trying to prevent the proximal malfeasance associated
with tamponade. Correlatively, there is the occasional stent or some
other process that has caused retrograde dissection into the
ascending aorta, and it is clear that it is not a primary ascending
aorta problem. How do you approach that?
Dr Bavaria. To clarify, what does the ascending aorta look like?
Is it an intramural hematoma (IMH) of the ascending aorta, or is it
a true full-blown double-barrel aorta?
Dr Calhoun. The ascending aorta has hematoma, but on inspec-
tion, the tear is perhaps up in the arch at the level of the carotid
artery or somewhere where acutely going after it would require
a much more extensive operation.
Dr Bavaria. Dr Miller, you have an acute type A aortic dissec-
tion with 2 barrels, and you have your primary tear site in the distal
arch or descending aorta. What is your protocol?
Dr Miller. Or an acute type A dissection where you find a tear
in the distal arch, I think was the question. I would go after it in
a younger healthier patient. Why be afraid of going after it and
doing the right operation? If it is in the proximal descending
artery, however, which happens, then it is a lot stickier wicket.
There is one neat trick we have not heard discussed yesterday
or today, which is the Djumbodis device in Europe, which is
a big bunch of nitinol that you throw down there, and it just gently
pushes the flap out. That might help. Or you can do the open
E-vita, which we have heard about from Essen, or you can do
an antegrade stent graft. If it is way beyond and you are not going
to be able to get to it directly surgically, you might want to think
about that. I caution everyone when I say that, because Kazui
himself has never been able to prove that the late reoperationgery c December 2010
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in whom he performed a total arch and a short elephant trunk,
compared with his historical series. Therefore going the extra
mile, doing something downstream, still lacks proof of efficacy,
and we all know it has risk.
Dr Bavaria. Dr Deeb, you have a type A aortic dissection, and
you get in there and really the primary tear site is in the distal arch or
descending aorta. What do you do at Michigan?
Dr Deeb. I think our approach is similar to Dr Miller’s. If it is
in the arch and we can see it, we are very aggressive. If it is just
beyond the left subclavian and I can get to it, I am very aggres-
sive. If you can see it and it is beyond the left subclavian, we
have done a couple of cases in which we have done hybrid pro-
cedures. We have stuck a stent down antegrade, put some mat-
tress stitches in to secure it, and then we have sewn our distal
to that and completed the arch. We will be very aggressive at
getting the tear.
Dr Bavaria. That might be the best way to do it. Dr Lansman, do
you have a comment?
Dr Lansman. I just wanted to add that over the years, I think we
very rarely replaced the whole arch. We have a fairly large experi-
ence with acute dissections. In almost every case we can do a hemi-
arch with the caveat that some of those are very extended
hemiarches, even extending into the proximal descending aorta.
Fortunately, most of the tears are on the lesser curvature, but
some extend toward the greater curvature, and most often you
can fashion the hemiarch to eliminate the tear.
Dr Bavaria. Let’s take that question a little further. You have an
acute type A dissection by definition, I suppose, but the ascending
arch component is really an IMH. The adventitial diameter is less
than 5 cm, the acute hematoma is less than 1 cm, and there is no
aortic insufficiency and no significant pericardial effusion. Would
the panel treat this medically or with surgical intervention?
Dr Lansman. Well, I can start by saying we have an N of 1, and
it was an 87-year-old man with a type A dissection, just as you
described, an IMH that presented after a couple of days, and we
were happy to watch it. On a computed tomographic (CT) scan
about a week or so later, it had converted to a real type A dissection,
and the patient underwent surgical intervention successfully. After
my review, we have decided to adopt the type of approach that
Dr Estrera so nicely laid out.
Dr Bavaria. Therefore again, we will put it that you really have
a type B dissection with retrograde IMH only, with the parameters I
just described. Let’s go down the panel. Dr Szeto, what would you
do for that, medically or surgically manage or maybe a stent graft?
Dr Szeto. Well, Joe, as you know, we have struggled with that at
our institution as well. A lot of it obviously will have to be guided
by the patient’s scenario. We tend to be more aggressive in younger
patients, and in 80-year-old or older patients we tend to become
more conservative. As you know, we have also had a recent expe-
rience with an 85-year-old woman with a similar clinical scenario
as you described. We watched her, and she ruptured in the hospital.
You remember that. Therefore it is a difficult question, but I think
most of it, at least in our hands, is driven by clinical presentation
and the status of the patient, and we tend to be more aggressive
when they are younger.
Dr Estrera. Yes, I agree regarding IMH, and we published
that. We are pretty aggressive. Having said that, you need toThe Journal of Thoracic and Cardindividualize, and obviously an older patient like that we might
watch. But in the majority of those cases, we observe that most
of them will convert, at least in the Western patient population
down in Houston. We know that a lot of them convert, and there-
fore we are pretty aggressive.
I want to make one comment about the typical dissection that
extends into the arch or where the tear is in the arch. Our philosophy
has been to be less aggressive and just take care of the ascending
and proximal arch. In our series of 366 patients, we did extensive
arch procedures in fewer than 5% of the patients. And the reality
of what we are seeing in follow-up, although I need to analyze these
data, is that the arch, for some reason, does not dilate that much. It is
really the proximal descending aorta that dilates. If the tear starts at
the proximal descending aorta, I will not go after it. I will take care
of the problem that is going to kill the patient, which is pericardial
tamponade. I will take care of the ascending aorta first.
Dr Bavaria. Christoph, is there any role for stent grafting in the
scenario in which you have a type B dissection with a retrograde
proximal IMH?
Dr Nienaber. Well, if you are talking about IMH, you have to
consider that no tear is available. Therefore there is actually by def-
inition no type B dissection with an IMH. It is extending to the
proximal aorta but is basically a dissection in evolution, and that
is considered to be an indication for surgical intervention as long
as, in type B dissection, the proximal aorta is involved. Therefore
I would not recommend any stenting in a situation like that, which
is a growing involvement of the ascending aorta. An IMH in the
ascending aorta has to be individualized.We consider it a dissection
in evolution and only very sick comorbid patients are patients to be
watched; others should undergo operations in an elective fashion
very soon.
DrGriepp. I just had a question for the other panelists. I wonder
whether anybody had ever seen cerebral embolization in a type A
IMH that converted to a type A dissection. Where did all the
clot go?
Dr Bavaria. Good question. I have seen cerebral malperfusion
from a true lumen collapse. I do not think I have ever seen embo-
lization. Has anybody on the panel ever seen that?
Dr Acher. Actually, we did have a patient with Marfan syn-
drome with an acute type B dissection in whom we had done
a type IV, quite large aneurysm a few years before. One of the com-
plications of his type B dissection was a stroke, not from malperfu-
sion but from an embolus because of the proximity of the dissection
to the left carotid artery.
Dr G. Di Luozzo (New York, NY). This question is actually for
Wilson. In your series of complicated type B dissections treated
with endovascular techniques, what was your paraplegia rate? After
paving a descending thoracic aorta extensively, how do you man-
age the blood pressure (because that could be tricky)? Do you
put lumbar drains in these patients?
Dr Szeto. Those are very good questions. In our series, strik-
ingly and contrary to the other series published, the risk of spinal
cord ischemia was not insignificant. Our rate of spinal cord ische-
mia was almost 13%. Having said that, most of these were not per-
manent: only 2 of these patients actually had permanent spinal cord
ischemia resulting in paraplegia.
In terms of how we would manage these patients intraopera-
tively, at least in this population, the acute complicated patientsiovascular Surgery c Volume 140, Number 6S S143
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drain preoperatively because of the emergent nature of the opera-
tion. If neuromonitoring is available, we use somatosensory evoked
potentials and motor evoked potentials (MEPs), and postopera-
tively we tend to try to wake the patients earlier to get a more reli-
able neurologic examination. If clinically necessary, we intervene
with either a lumbar drain or volume expansion and so on. There-
fore it is a difficult situation or scenario. These patients are often
very sick.
Blood pressure management, I agree, is quite tricky. In patients
with malperfusion, we tend to be a little bit more liberal with having
a higher blood pressure as opposed to patients with rupture, but it is
a fine balance.
Dr Griepp. I just wanted to ask whether any of those patients
have had compromise of the hypogastric circulation caused by their
dissection. Because the data suggest that if you have had a previous
abdominal aortic operation and then you have a thoracic aortic
operation, your incidence of paraplegia is higher. I suspect that
many of those cases of spinal cord injury are explained by loss of
the hypogastric circulation at the abdominal operation.
Dr Szeto. You are absolutely right. One of our patients had pre-
vious abdominal aortic aneurysm surgery. However, what was
common for both of those patients was extensive coverage of the
thoracic aorta. One of them was a man with previous abdominal
aortic surgery who had a rupture that we covered from the left sub-
clavian artery down to the celiac artery. The second patient had
severe malperfusion that required a so-called full metal jacket,
where just 1 endograft proximally covering the primary tear site
was not enough to reverse the malperfusion syndrome, and he
had subsequent distal endografts. There were not only covered
stents in the thoracic aorta but also bare metal stents in the infrarenal
abdominal aorta and the iliacs. Therefore even though the numbers
are small and I cannot make strong conclusions based on that, I
agree that hypogastric compromise is certainly a risk factor for
which to watch.
Dr B. Youdelman (Philadelphia, Pa). We have had 2 patients in
whom we were doing stent grafts for acute type B dissections who
had retrograde hematomas. One progressed as we were following
him, and we wound up doing a type A repair. The other we
watched. I have not heard the incidence of the retrograde hematoma
or type A dissection from the group, and I was wondering what
everybody is seeing with their stent grafts for acute dissection
and what everybody is doing about them.
DrMiller. Everybody has his or her numbers, and the incidence
is very high. It is probably a function of the type of stent graft you
are using for the acute complicated type B dissection. The Talent
and maybe even the Valiant grafts are the worst offenders based
on the European cooperative study and the data from China and
Shanghai; the number of stent grafts being used in China is phe-
nomenal. However, they have a serious retro A problem, and the
stent graft used in Shanghai, I think, is a knockoff of the Talent.
There was also a recent report from Italy with a very high incidence.
As we all know, these retrograde hematomas can be highly lethal. It
depends on the type of stent graft. I do not think it depends on how
much you cover.
Dr Bavaria. Christoph, you have personal experience with this.
What is your personal retrograde type A dissection rate for all the
stent grafts that you put in for dissections?S144 The Journal of Thoracic and Cardiovascular SurDr Nienaber. Fortunately, it is low. But in the Investigation of
Stent Grafts in PatientsWith Type BAortic Dissection (INSTEAD)
study we mentioned, we have one case that was probably due to
a pre-existing IMH that was not picked up on initial imaging. How-
ever, returning to the reason for retrograde dissection, I think it is not
only the type of stent graft but also the handling. There should be no
poststent ballooning in the proximal end of the stent, there should be
no oversizing, and there should be, obviously, no aggressive prox-
imal end of the stent graft that could potentially cause rupture or
penetration through the intimal layer of the affected aorta. Therefore
there are various elements. One is the nature of the stent, but more
important, I personally think, is the handling of the procedure.
Dr Bavaria. Wilson, in the 45 patients that you had, what was
your retrograde type A dissection rate?
Dr Szeto. As you know, we had 3.
Dr Bavaria. That is 6%.
Dr Szeto. We had 3, and they were delayed. They were all found
on a postoperative surveillance scan at 3 months or later.
Dr Bavaria. To echo Dr Miller, I have just reviewed 500 of
these from Hong Kong. The retrograde dissection rate was 3%
for acute dissections, both complicated and uncomplicated batched
together.
Dr Miller. Before we leave that topic, I think it behooves the
manufacturers to come up with a dissection-specific device: maybe
the LP Zenith by Cook is going to be that, with nitinol instead of
stainless steel, or maybe the Gore C-TAG might be a little kinder
and gentler on the proximal arch.
Dr Bavaria. We probably are going to get better stent grafts.
That is going to have to be key, or else we are not going to be
able to gomuch farther with uncomplicated type B dissection cases.
That is for sure.
Dr D. Spielvogel (Valhalla, NY). This is for the panelists but
also for Dr Deeb. I have been intrigued by your approach to the dif-
ficult patients with malperfusion. We approach malperfusion with
fenestration as you illustrated, and we do not use any endografts.
The endografts with fenestration you do not see. We get retrograde
type A dissections, and we do not see paraplegia. My question
really is this: Have you looked at the group of patients with rupture,
and is there a way to tease out that group and maybe intervene
before rupture? When we talk about malperfusion, we kind of
lump it all together. What we do not see are data like the pH of
the patient and the level of lactic acidosis. The patients who do
very poorly are the acidotic patients with visceral malperfusion:
superior mesenteric artery occlusion or obstruction. Therefore is
there a way of separating out that group in whom one can intervene
and prevent loss through rupture?
Dr Bavaria. So, Mike, answer that. But also, you had a lot of
ruptures. How many of the ruptures were from type A ascending
stuff, and how many were actual ruptures from the fenestration
procedure distally?
DrDeeb. They were all ruptures in the proximal descending tho-
racic aorta. We autopsied them. None of them were retrograde type
A: we didn’t have those. None of them were down in the abdomen
where we had done the fenestration. They were all in the proximal
descending thoracic aorta. You can say that the procedure did not
have anything to do with it. My answer is that it did because we
changed the hemodynamics. We went in and instrumented the
patient. Doing that procedure does not decrease the risk of rupturegery c December 2010
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have no complications and yet are treated medically, the big risk is
rupture. The incidence of that is relatively low. This incidence was
7%, I believe. I think it is slightly higher than in those treated med-
ically, and it might have something to do with the instrumentation
that we did on these patients. We have not looked at these patients
specifically and run risk factors on them. That might be something
that we should do, to try to identify who is at risk of rupturing. As
for this patient population, once identified, should they have an
endovascular approach rather than the percutaneous fenestration–
stent? Are these patients you would go right after with thoracic
endovascular aortic repair (TEVAR)?
Dr Miller. Well, both of you are taking the fenestration–stent
experience as the benchmark to which we should compare TEVAR
for acute complicated B.
Dr Deeb. I am glad you asked that. No, we really were not.
Dr Miller. I am glad you are not because you are going to lose.
Dr Deeb. What we did is that we read the literature, and every-
one said that we have to get better technical devices to work with,
that we need to gain more data, and that we need to compare
TEVAR with another procedure. When we put in our article for
the American Association for Thoracic Surgery and we read the
conclusion, we said that fenestration–stent should be used for
comparison. I looked at my young partner, Himanshu, and said
that this approach was going to get trashed. Therefore what we
need to do is put something out there that is going to elicit a reac-
tion. I said that we should put a benchmark out there, and it
seemed to work because we got it on the program. We do not
think the fenestration–stent is a gold standard to which one should
compare anything, but we do know it is a procedure that has been
out there that has some effectiveness, and we can get some data-
driven outcomes. Everyone wants data-driven outcomes. Here is
something we have done for a long time.
Dr Miller. But there are data now, and, David, what you are
doing now makes me really surprised. Why? It is a benchmark,
and it is excellent, but if you look at that late attrition, you do not
see that in the Penn group or in our 16 patients. You do not see
that late attrition if you cover the primary intimal tear with a short
stent graft.
Dr Bavaria. Wait a minute. We have 1000 clinical aortic sur-
geons out here. I want to go right down this panel. You have an
acute complicated type B dissection. Is the first order of therapy
a stent graft, or is fenestration the first order of therapy?
DrDeeb. We did fenestration and stenting because we had noth-
ing else. There is no approved stent graft in the United States to use
for type B dissection. Our institution highly discourages us from
using it off label. Now that we are in the C-TAG trial, we are going
to stent endovascularly. We are going to get some experience with
that. If we do not see a marked difference, we are thinking about
doing a randomized prospective trial.
Dr Schepens. Stent grafting.
Dr Acher. We also are in the C-TAG trial, and therefore
we would only stent those. We published a series of medical
management of about 81 type B dissections, 20% of which were
complicated.
Dr Bavaria. The medical management of complicated type B
dissection has a mortality of between 30% and 70%.
Dr Acher. That is what we found when we operated.The Journal of Thoracic and CardDr Nienaber. There is clearly no room for primary fenestra-
tion. The first step would always be stent grafting in cases of
malperfusion.
Dr Bavaria. I think we are getting a consensus. Anybody else?
We know Dr Miller’s results.
Dr Estrera. You have got to cover the tear with a stent graft.
Dr S. Takamoto (Tokyo, Japan). Dr Bavaria told us about IMH
and type B dissection. What he described is thrombus formation in
the false lumen in the ascending aorta: that is a complete miscon-
ception of IMH. IMH should not have a tear. For the study in Japan
of about 200 type B dissection–related IMHs, that was the initial
diagnosis. In one third of the patients, a false lumen becomes pat-
ent. Therefore sometimes the tear is hidden at the time of initial
diagnosis. Only the CT examination shows that diagnosis.
However, if I see images of a false lumen obtained by means of
transesophageal echocardiographic analysis, the false lumen is
not completely thrombosed at the first moment: in some parts the
thrombus is there, but in other parts fluid exits and is moving.
IMH is not an accurate diagnosis for surgeons; it is terminology
for radiologists and is not good for surgeons. We should take
care of that kind of disease as aortic dissection with a thrombosed
false lumen. What do you think about that? IMH is not an appropri-
ate term for surgeons.
Dr Bavaria. My point is that you have this proximal aortic
event, which is kind of an IMH, but the primary problem is in
the proximal descending aorta, and how should you approach
that? The problem is that if we do a sternotomy and an ascending
hemiarch and whatever else, this is not really affecting the major
issue. We might be doing kind of a lesser operation conceptually
than perhaps we should be doing, which is to tackle the primary
event. Maybe just coming across the primary tear site with a stent
graft, for example, might depressurize the whole thing and stop the
process from going any further. It was the concept that we, as car-
diac surgeons, are going in through the front when the major prob-
lem is coming in from the back.
Dr Takamoto. What you are describing is an acute aortic dissec-
tion with a thrombosed false lumen in the ascending aorta. That is
not an IMH. An IMH should not have a tear.
Dr Estrera. Dr Takamoto is exactly correct. IMH really is a
radiological diagnosis, if you think about it. We just cannot see
that tear by means of CT scan, and that was one of the flaws of
our article. We made that diagnosis based on a CT scan or on intra-
operative findings. The reality is that there are probably a lot of
those that occurred between our screening in terms of identifying
IMH, and there probably is a tear that you just cannot see on
a CT scan.
Dr Bavaria. I agree with that. I want to do a couple of questions,
but there is one question I want to ask Drs Griepp and Estrera. I
have heard Dr Griepp say that he has never seen anyMEPs decrease
after thoracoabdominal surgery, and Dr Estrera says it is 50% or
greater. Can you guys educate us about the MEPs?
Dr Griepp. I suspect Dr Estrera has much more rigid criteria
than we do. What I have said and I think is true is that we almost
never see a situation in which the MEP decreases that we cannot
get it back to where it was a few minutes before with hemodynamic
manipulation. I am sure it has occurred once.
Dr Estrera. We do have pretty strict criteria that are used by
a neurophysiologist at the time. You have got to think about theiovascular Surgery c Volume 140, Number 6S S145
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that he will expose everything and then clip the intercostals off con-
secutively in a pulsatile patient. Our technique is that we clamp the
aorta, fillet it open, and then we see whether neuromonitoring
changes occur. Therefore it is really a different physiology. We
have no pulsatile flow; Dr Griepp has pulsatile flow: this is a signif-
icant difference between approaches. I think what needs to be rec-
ognized is the concept of a collateral network that he has
established because I think this changes the way one thinks about
how to protect the spinal cord.
Dr S. Yetman (New Haven, Conn). I have a question for the
panel in terms of your management strategy in the patient who pres-
ents with acute aortic dissection and peripheral neurologic deficits.
The patient is still interactive, and therefore we are not talking about
coma or anything like that. What are your parameters in taking this
patient to the operating room? Is there a time interval from the onset
of symptoms, and if there is a time interval, what medical manage-
ment would you provide for this patient? Does it include the use of
heparin?
Dr Bavaria. Michael Deeb, do you want to start off with that
one as a kind of a delay guy?
Dr Deeb. That is an interesting question because we just had
a young male patient who presented with a dense hemiplegia
who was awake, and the question was, should we take him to
the operating room? As we were moving this patient from the
emergency department to the intensive care unit, he became
somnolent. We got a CT scan of the head; it showed a small infarct
in that area, and I thought that if I heparinized the patient and froze
him down, he would not be getting any better. Some people were
pushing me to do it. We sent him for a magnetic resonanceS146 The Journal of Thoracic and Cardiovascular Surangiography: he had a big area of infarct, and within 2 hours, he
herniated and died. Therefore that is a very tough question. I do
not think one does anyone who has a significant central neurology
intracranial deficit any good by cooling down their brain and
heparinizing them.
Dr Bavaria. Dr Tsagakis, what are you doing at Essen?
Dr Tsagakis. With a central neurologic deficit?
Dr Bavaria. Yes.
Dr Tsagakis. It depends, of course, on the condition of the
patient. If the patient is awake, then we will operate: this is clear.
If the patient is not and we have imaging of the brain, which is
not very common, on which we see a very big injury on the left
side of the brain, we do not perform the operation. We had such
a case last year.
Dr Bavaria. Your follow-up question was about timing?
Dr Yetman. Yes. Is there any timing involved in terms of the
onset of symptoms versus when they present to you that determines
whether you operate on the patient?
Dr Tsagakis. With regard to neurologic injury, actually you
have no time. You must operate or not.
Dr Bavaria. I think that is an important question. If the neu-
rologic symptoms have been there for a while, we would usually
not take them to the operating room right away if there is a big,
dense neurologic deficit. However, if the patient presents in less
than 6 to 8 hours, we would actually take those patients to the
operating room and reperfuse them, and we have had fairly rea-
sonable results with that. It is not 100%, obviously, but it is fairly
reasonable.
Unfortunately, we are going to have to cut it off here. Thank you
very much.gery c December 2010
